HOME >> MEDICINE >> NEWS
Preliminary study shows high-dose coenzyme Q10 slows functional decline in Parkinson's patients

A national clinical trial with 80 Parkinson's disease patients has shown that high dosages of a naturally occurring compound, coenzyme Q10, slowed by 44 percent the progressive deterioration in function that occurs in the disease. The greatest benefit was seen in everyday activities such as feeding, dressing, bathing and walking.

The study's coordinators caution that while encouraging, the therapy needs to be tested in a larger trial with hundreds of patients before this treatment can be recommended.

Published in the Oct. 15, 2002 issue of the American Medical Association's Archives of Neurology, the study was conducted at 10 sites by the Parkinson Study Group, under the direction of principal investigator Clifford Shults, M.D., professor of neurosciences, University of California, San Diego (UCSD) School of Medicine, and chief of the Neurology Service at the VA San Diego Healthcare System. Parkinson's disease is a degenerative disorder of the brain in which patients develop tremor, slowness of movement and stiffness of muscles. It affects approximately 1 percent of Americans over the age of 65. Although certain drugs, such as levodopa, can reduce the symptoms of Parkinson's disease, no treatment has been shown to slow the progressive deterioration in function.

The selection of coenzyme Q10 as a potential treatment for Parkinson's was based on work carried out over the past decade by Shults, Richard Haas, M.D., UCSD professor of neurosciences, and Flint Beal, M.D., professor and chair of neurology, Weill Medical College of Cornell University.

Shults explained that mitochondria produce the energy-containing molecules that supply energy to chemical reactions in cells and that coenzyme Q10 plays an integral role in that process. He further explained that coenzyme Q10 is also a potent antioxidant. Over the past several years, research by Shults, Haas and Beal showed that mitochondrial function is impaired in patients with Park
'"/>

Contact: Sue Pondrom
spondrom@ucsd.edu
619-543-6163
University of California - San Diego
14-Oct-2002


Page: 1 2 3 4

Related medicine news :

1. Preliminary results are promising in Alzheimers gene therapy trial
2. Preliminary report suggests combination therapy may help treat SARS
3. Preliminary study finds stem cells in blood restore damaged heart muscle
4. Preliminary study suggests endomitriosis could contribute to infertility
5. Preliminary US study findings support excellent results with CYPHER Sirolimus-eluting Stent
6. Preliminary Study Proves Centuries Of Herbalists Right About Echinacea
7. ACTG 315 Preliminary Results: Drug Cocktail Restores Partial Immune Function
8. First head-to-head study to compare lidoderm patch and Celebrex in treating pain
9. UMaine study looks at infants and chronic nighttime crying
10. Chronic pain treatments more effective when taken together, new study shows
11. UNC study: Most N.C. family practitioners engage in unrecognized community service

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/23/2017)... ... March 23, 2017 , ... Inflow IQ & Inflownomics of Raleigh, NC ... on a solid foundation. As experts in dangerous situations the Inflow IQ team ... soon. Inflownomics deliver ripe, fresh, clean & refreshing knowledge systems that enhance life. ...
(Date:3/23/2017)... ... 2017 , ... On 2 March 2017, the United States ... Command’s Patriot Award. The award was presented by the USSOCOM Commander, General Raymond ... its significant and enduring support to the command. , Accepting the award ...
(Date:3/23/2017)... ... ... “Beyond and Back”: a true-life testimony of tragedy and the miraculous power ... Rose, a wife, mother and grandmother committed to sharing her many spiritual adventures which ... new book presents actual events in the life of her family, which validate her ...
(Date:3/23/2017)... ... March 23, 2017 , ... “The Trainer”: an ... published author, Scotty, a fiction writer with an active imagination and an enthusiasm for ... book follows the tale of Wild Bill Hart, who sat looking at the thirty-three ...
(Date:3/22/2017)... ... March 23, 2017 , ... Catalent Pharma Solutions, the ... and consumer health products, today announced that it had won the ‘Clinical Supply ... the Suntec Singapore International Exhibition & Convention Centre, Singapore. The award was presented ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... 2017 ReNeuron reported in December 2016 ... chronic stroke patients, despite not meeting the three-month time frame ... Action Research Arm Test (ARAT). As a result, the company ... clinical study in 2017. Beyond CTX, we expect safety and ... and Phase I data from its critical limb ischaemia (CLI) ...
(Date:3/22/2017)... -- ReportsnReports.com adds Global Vagus Nerve Stimulation ... global vagus nerve stimulation market analyst says one trend ... invasive VNS procedures. Few years ago, VNS procedures were ... high standards of healthcare infrastructure. ... Browse 30 Exhibits, ...
(Date:3/22/2017)... , March 22, 2017 Ampio ... the development of Ampion™, a low molecular weight ... today announced that it is re-issuing its previous release ... incorporate certain disclosures that are required under the ... below are these additional disclosures along with the ...
Breaking Medicine Technology:
Cached News: